BIOMAT Database Logo BIOMAT Database Logo

Epoprostenol for pulmonary hypertension in scleroderma. 2000

E S Klings, and H W Farber

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis

Related Publications

E S Klings, and H W Farber
Epoprostenol for primary pulmonary hypertension.
February 1996, The Medical letter on drugs and therapeutics,
E S Klings, and H W Farber
Epoprostenol therapy for primary pulmonary hypertension.
August 1999, Critical care nurse,
E S Klings, and H W Farber
Intravenous epoprostenol for primary pulmonary hypertension.
May 1996, The New England journal of medicine,
E S Klings, and H W Farber
Intravenous epoprostenol for primary pulmonary hypertension.
May 1996, The New England journal of medicine,
E S Klings, and H W Farber
Epoprostenol Therapy for Pulmonary Arterial Hypertension.
January 2015, Acta medica Okayama,
E S Klings, and H W Farber
Epoprostenol in pulmonary arterial hypertension.
January 2009, Expert opinion on drug metabolism & toxicology,
E S Klings, and H W Farber
Epoprostenol in primary pulmonary hypertension.
March 1999, The Annals of pharmacotherapy,
E S Klings, and H W Farber
Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.
May 1999, The Journal of rheumatology,
E S Klings, and H W Farber
Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.
October 2009, The Journal of rheumatology,
E S Klings, and H W Farber
Epoprostenol (prostacyclin) and pulmonary hypertension.
March 2000, Annals of internal medicine,
Copied contents to your clipboard!